Logo

World's First FDA IDE Coronary Patient Treated With a DEB

NYON, Switzerland, July 11, 2020 /PRNewswire-AsiaNet/ -- MedAlliance has announced enrollment of the first patient in its study of SELUTION SLR(TM) 014 DEB (http://medalliance.com/product/ )for the treatment of In-Stent Restenosis (ISR). This is the first DEB accepted by the FDA for its 'Breakthroug...

Authors: LATEST ASIANET NEWS RELEASES

Read more

Asian Spectator by NewsServices.com - office@NewsServices.com - 1300 660 660